The gut–brain axis runs through the vagus nerve — and it is now a subject of measurable science.
The autonomic nervous system, and specifically the vagus nerve, is a two-way channel between the gut and the central nervous system. In irritable bowel syndrome and functional dyspepsia, this connection is no longer a hypothesis but a measurable part of the clinical picture. Below, we show what the science actually shows — honestly, with sources.
Do you recognise these complaints in yourself or in a patient?
Functional gastrointestinal disorders (IBS, functional dyspepsia) are among the most common reasons for a gastroenterology consultation.
Irritable bowel syndrome and functional dyspepsia fall under what are known as disorders of gut–brain interaction (DGBI, per the Rome IV classification) — conditions in which communication between the digestive tract and the central nervous system, carried to a large extent via the vagus nerve, is disrupted.
Self-assessment, not self-diagnosis. Diagnosis and the evaluation of alarm symptoms require a gastroenterologist.
The link between vagal tone and IBS has now been measured — quantitatively, in real patients.
Lower vagal tone in IBS
A meta-analysis of 11 studies (n=392) shows consistently lower HF power and a higher LF:HF ratio in IBS patients versus healthy controls — a marker of reduced parasympathetic tone. The link is correlational and does not prove causation (Zhang et al., meta-analysis of HRV in IBS).
A real response to vagus stimulation (taVNS)
An RCT in IBS-C (n=40) compares transcutaneous auricular vagus nerve stimulation (taVNS — a different method and device from NESA) with placebo. At week 4, VAS pain scores dropped to 2.90 in the active group versus 5.25 with placebo (p<0.001), with a responder rate of 85% versus 10%. The same study found no significant change in gut microbiome diversity (Liu, Lv, Yin et al., Am J Gastroenterol, 2025).
Confirmed in a pooled analysis
A systematic review with meta-analysis of 6 RCTs (n=356) confirms a significant pooled improvement in VAS abdominal pain (mean difference −1.76; p=0.003), stool consistency, and overall IBS-SSS score.
A large multicentre trial of taVNS in chronic constipation (the general population, not just IBS-C) was stopped early for futility — the stimulation did not differ from placebo (2025, registry NCT05723731). This matters: the positive signal above appears specific to IBS-C, not automatically transferable to constipation as a whole.
A systematic review in Gastroenterology Report (Veldman, Hawinkels, Keszthelyi, 2025) describes the overall picture as "promising," but based on only 7 small, mostly unblinded studies — so far there are no well-controlled trials in adults with inflammatory diseases of the digestive tract.
Sources: Zhang et al., meta-analysis of HRV in irritable bowel syndrome (PubMed 23927739) · Liu J, Lv C, Yin M et al., Am J Gastroenterol 2025;120:2139–2153 · systematic review and meta-analysis, 2025/2026 (PubMed 42506049) · multicentre trial of taVNS in chronic constipation, stopped for futility, 2025 (NCT05723731) · Veldman F, Hawinkels K, Keszthelyi D, Gastroenterology Report, 2025. taVNS is a different method and device from NESA XSIGNAL® — cited as context for the research field, not as data on NESA.
The vagus nerve also carries metabolic signals — but for now this is a laboratory mechanism, not a treatment.
Alongside the IBS research above, another, separate line of science studies the role of vagal afferent fibres in carrying signals from GLP-1 (glucagon-like peptide-1) receptors — signals linked to satiety and gastric emptying. This science is real and solid, but it is entirely preclinical.
In rodents and in preclinical models it is well documented that vagal afferent neurons carry GLP-1-receptor signalling involved in the regulation of satiety and gastric emptying (summarised in J Physiol Sci 2024;74:11 and related reviews). Real science — but at the level of mechanism, not at the level of clinical outcomes in humans.
Human studies of taVNS for weight or metabolic outcomes are only just beginning to recruit participants — a protocol was registered in 2025, with no published results to date.
No published clinical study in humans has tested NESA or a comparable device for weight, appetite, GLP-1 levels, or metabolic syndrome as a primary endpoint. The information above is presented for educational purposes, to show the direction of scientific interest in the vagus nerve — not as an indication, protocol, or promise of effect on weight or appetite.
Sources: J Physiol Sci 2024;74:11 and related reviews of vagal GLP-1 signalling · registered clinical trial protocol on taVNS and metabolic outcomes, 2025 (no published results to date).
Non-invasive modulation of exactly this system.
NESA XSIGNAL® works with controlled microcurrents through the limbs, aimed at the balance between the sympathetic and parasympathetic nervous system — the same system through which the vagal signal between gut and brain travels, documented above as disrupted in IBS.
NESA may help the autonomic nervous system regain its balance — but only within this mechanism: there is no study of NESA specifically in IBS, functional gastrointestinal disorders, or metabolic conditions. If such a balance is restored, it is precisely this restored function of the nervous system itself — not the device — that may contribute to easing related complaints.
There is no published clinical study of NESA specifically in IBS, functional gastrointestinal disorders, or metabolic conditions.
We do not claim otherwise, nor do we imply it. Above we showed what has actually been measured — with a different method (taVNS) and in preclinical models — not with NESA itself.
NESA may help manage autonomic imbalance associated with gastrointestinal complaints — but it does not cure IBS, functional dyspepsia, or metabolic disorders, and it does not replace a doctor.
NESA makes no promise of a cure for IBS, functional dyspepsia, or metabolic conditions — the support is directed at the autonomic nervous system, not at the disease itself.
In the presence of alarm symptoms (blood in the stool, unexplained weight loss, anaemia, a family history of colorectal cancer, and similar), a timely gastroenterology evaluation is mandatory before considering any additional intervention.
Absolute contraindications (pacemaker, pregnancy, active electrical implants) follow the device's IFU.
Discuss your specific case with us.
For therapists and doctors: we explain the NESA mechanism, the available protocols, and how to assess whether it is a suitable tool within the patient's overall plan.
Specialised materials for you
Leave your email, confirm with one click — and the NESA presentations (BG · DE · EN) arrive automatically. Free, no spam.